Literature DB >> 1543676

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases.

V V Villars1, T C Jones.   

Abstract

Terbinafine (Lamisil) is an antifungal drug, belonging to a class of drugs called the allylamines, which has recently become available for clinical use. This is a report of four special features which emerged during evaluation of the systemic use of orally administered terbinafine in the treatment of 2500 patients during the last 5 years. These features include: (i) distribution of terbinafine in skin, hair and nail tissue; (ii) use in short-duration treatment of chronic tinea pedis and onychomycosis; (iii) use in patients with serious infections often associated with local or generalized immunological defects; and (iv) tolerability and safety of the drug. The diffusion of terbinafine into thickened, chronically infected tissue and into nails, and its recognized fungicidal action are the most likely features responsible for its success in the treatment of chronic fungal diseases, including those with immunological defects. Terbinafine is well tolerated, particularly when compared with other available systemic antifungal drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543676     DOI: 10.1111/j.1365-2133.1992.tb00013.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

Review 1.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors:  Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy.

Authors:  P E Verweij; N J Cox; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 4.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

5.  In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.

Authors:  N S Ryder; S Wagner; I Leitner
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 7.  Mechanistic Insights of Formulation Approaches for the Treatment of Nail Infection: Conventional and Novel Drug Delivery Approaches.

Authors:  Agrawal Vikas; Patel Rashmin; Patel Mrunali; Rahul B Chavan; Thanki Kaushik
Journal:  AAPS PharmSciTech       Date:  2020-01-14       Impact factor: 3.246

8.  Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.

Authors:  Yoshiyuki Tatsumi; Mamoru Yokoo; Hisato Senda; Kazuaki Kakehi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

9.  Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

Authors:  A K Gupta
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

Review 10.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.